Skip to main content

Table 1 Characteristics of patients with Muckle-Wells syndrome (MWS) treated with interleukin-1-blocking therapy

From: Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

  Anakinra
cohort
n= 12
Canakinumab cohort
n= 14
Demographics   
Male/female patients 3:9 5:9
% females 75 64
Median age at MWS diagnosis in years (range) 19.0
(3.0 to 65.5)
27.0
(3.0 to 72)
Median age at anti IL-1 therapy in years (range) 21.0
(3.0 to 66.5)
29.0
(4.0 to 74.5)
NLRP3 mutation   
Mutation subtypes:
   E311K No (%)
   T348M No (%)
   V198M No (%)
7/12 (58%)
3/12 (25%)
2/12 (17%)
10/14 (71%)
2/14 (14%)
2/14 (14%)
Follow-up   
Median follow-up
in months (range)
52 (23 to 115) 50 (23 to 110)